Evidence map›Paper›PMID 28419407›Full record

Trial reportBritish journal of haematology2018

University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.

Natalie Galanina, Sonali M Smith, Chuanhong Liao, Adam Petrich, Bernadette Libao, Ronald Gartenhaus, Jason R Westin, Kenneth S Cohen, James A Knost, Walter M Stadler and 4 more

Abstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Natalie GalaninaDepartment of Hematology/Oncology, University of California San Diego, Moores Cancer Center, San Diego, CA, USA.
Sonali M SmithDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Chuanhong LiaoDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Adam PetrichDivision of Hematology/Oncology Northwestern University, Chicago, IL, USA.
Bernadette LibaoDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Ronald GartenhausDepartment of Hematology/Oncology, University of Maryland, Baltimore, MD, USA.
Jason R WestinMD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1824-2337
Kenneth S CohenDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
James A KnostIllinois Cancer Care, Peoria, IL, USA.
Walter M StadlerDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Austin DoyleNational Cancer Institute, Bethesda, MD, USA.
Theodore KarrisonDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Leo I GordonDivision of Hematology/Oncology Northwestern University, Chicago, IL, USA.
Andrew M EvensDivision of Hematology/OncologyTufts University School of Medicine, Boston, MA, USA.

Funding

Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos · 2014 to 2026
$20.4M
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic ParadigmR01CA164311 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI EVENS, ANDREW M, GARTENHAUS, RONALD B · 2012 to 2015
$1.4M
NCI NIH HHS R01 CA164311NCI NIH HHS UM1 CA186688
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overBenzimidazolesChicagoDisease-Free SurvivalFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedSurvival RateAZD 6244BenzimidazolesMEK inhibitionnovel therapiesrelapsed/refractory DLBCLselumetinib

Identifiers

PMID28419407
PMCPMC5785463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.